The role of cytokines in the pathogenesis of rheumatoid arthritis

Rheumatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 3-7

  Feldmann, M ^a   Maini, R N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cytokines; IL 1; Rheumatoid arthritis; TNF ; Treatment

Indexed keywords

CYTOKINE; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANGIOGENESIS; BONE DESTRUCTION; CARTILAGE DEGENERATION; CONFERENCE PAPER; HUMAN; JOINT; LEUKOCYTE; PATHOGENESIS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RHEUMATOID ARTHRITIS; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032692402     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
2. Berg P, Singer M. Genes and genomes. New York: University Science Books, 1991.
3. Pettipher ER, Whittle BJR. Prostaglandins. In: Delves PJ, Roitt I, eds. Encyclopedia of immunology, 2nd edn. London: Academic Press, 1998:2024-8.
4. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-5.
5. Di Giovine FS, Nuki G, Duff GW. Tumour necrosis factor in synovial exudates. Ann Rheum Dis 1988;47:768-72.
6. Fava RA, Olsen NJ, Spencer-Green G et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180:341-6.
7. Feldmann M, Brennan FM, Chantry D et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 1990;51:480-6.
8. Firestein GS, Xu W-D, Townsend K et al. Cytokines in chronic inflammatory arthritis. 1. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988;168:1573-86.
9. Hirano T, Matsuda T, Turner M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-1801.
10. Hopkins SJ, Meager A. Cytokines in synovial fluid II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol 1988;73:88-92.
11. Koch AE, Kunkel SL, Burrows JC et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1991;147:2187-95.
12. Miossec P, Naviliat M, D'Angeac AD, Sany J, Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis Rheum 1990;33:1180-7.
13. Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989;264:11966-73.
14. Wahl SM, Allen JB, Wong HL, Dougherty SF, Ellingsworth LR. Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium. J Immunol 1990;145:2514-9.
15. Buchan G, Barrett K, Fujita T, Taniguchi T, Maini R, Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2), IL-2 receptor and IFN-γ. Clin Exp Immunol 1988;71:295-301.
16. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988;73:449-55.
17. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;ii:244-7.
18. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
19. Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin-1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation and fever. J Exp Med 1985;162:1208-15.
20. Buttle DJ. Lysosomal cysteine endopeptidases in the degradation of cartilage and bone. In: Davies E, Dingle JT, eds. Immunopharmacology of joints and connective tissue. London: Academic Press, 1994:119-28.
21. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991;21:2575-9.
22. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89:7375-9.
23. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
24. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum 1993;36:1681-90.
25. Elliott MJ, Maini RN, Feldmann M et al. Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
26. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344:1125-7.
27. Maini RN, Breedveld FC, Kalden JR et al. Randomized placebo-controlled trial of multiple intravenous infusions of anti-TNF monoclonal antibody with or without weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
28. Moreland LW, Baumgartner SW et al Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
29. Moreland LW, Margolies G, Heck LW Jr et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
30. Rankin ECC, Choy EHS, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
31. Sander O, Rau R, van Riel P et al. Neutralization of TNF by Lenercept (TNFR-55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial. Arthritis Rheum 1996; 39(suppl.): S242(Abstract).
32. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-TNFα therapy of rheumatoid arthritis. Adv Immunol 1997: 64:283-350.
33. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
34. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1077-81.
35. Taylor PC, Chapman P, Elliott MJ et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy. Am Coll Rheumatol 1997;40:S80(Abstract).
36. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Reduction of angiogenic vascular endothelial growth factor following treatment of rheumatoid arthritis with anti-TNFα antibody. Arthritis Rheum 1998;41:1258-65.
37. van Dullemen HM, van Deventer SJH, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
38. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762-6.
39. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mortl. Nature 1998;392:296-300
40. Charles P, Elliot M, Davis D, Potter A, Kalden TR, Breedveld FC et al. Regulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163: 1521-8.